Clinical trial
Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in…
NCT00055562 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00055562 |
|---|---|
| Title | Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma |
| Official title | Multicenter, Randomized, Controlled, Double-Blind, Parallel-Group Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2 or IFN Based Therapy |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Melanoma, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | CC 5013 |
| Enrollment | 274 |
| Start date | Jan 1, 2003 |
| Completion | Dec 1, 2004 |
| First posted | Mar 6, 2003 |
| Last update posted | Jun 24, 2005 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: